Home > Insider Trading > Filing (0001104659-24-008799)

Filing Details

Accession Number:: 0001104659-24-008799
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-01-31 16:12:19
Reporting Period:: 2024-01-30

Accepted Time:: 2024-01-31 16:12:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1868279	Arrivent Biopharma Inc.	AVBP	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1055951	Orbimed Advisors Llc	601 Lexington Avenue, 54Th Floor New York NY 10022	Yes	No	Yes	No
1845804	Orbimed Capital Gp Viii Llc	601 Lexington Avenue, 54Th Floor New York NY 10022	Yes	No	Yes	No
1966835	Ltd Iv Advisors Orbimed	601 Lexington Avenue, 54Th Floor New York NY 10022	Yes	No	Yes	No
1966836	Orbimed Asia Gp Iv, L.p.	601 Lexington Avenue, 54Th Floor New York NY 10022	Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-01-30	821,827	$0.00	821,827	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2024-01-30	821,827	$0.00	821,827	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2024-01-30	469,615	$0.00	1,291,442	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2024-01-30	469,615	$0.00	1,291,442	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2024-01-30	222,222	$18.00	1,513,664	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2024-01-30	222,222	$18.00	1,513,664	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2024-01-30	821,827	$0.00	821,827	$0.00
Common Stock	Series A Preferred Stock	Disposition	2024-01-30	821,827	$0.00	821,827	$0.00
Common Stock	Series B Preferred Stock	Disposition	2024-01-30	469,615	$0.00	469,615	$0.00
Common Stock	Series B Preferred Stock	Disposition	2024-01-30	469,615	$0.00	469,615	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis.
These securities are held of record by OrbiMed Asia Partners IV, L.P. ("OAP IV"). OrbiMed Asia GP IV, L.P. ("Asia GP IV") is the general partner of OAP IV and OrbiMed Advisors IV Limited ("Advisors IV") is the general partner of Asia GP IV. OrbiMed Advisors LLC ("OrbiMed Advisors") is the advisory company of OAP IV. By virtue of such relationships, Asia GP IV, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OAP IV.
These securities are held of record by OrbiMed Private Investments VIII, L.P. ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
Reflects shares purchased in the Issuer's initial public offering.
The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering.